



## 37 Introduction

38 Persistence is defined as the ability of a genetically identical sub-population of the bacterial cells  
39 to survive the stress of the antibiotics and die at a slower rate than the rest of the population.<sup>1</sup> In  
40 time-kill experiments, a sharp decrease in the percentage of live cells occurs followed by a  
41 plateau survival rate due to the slow rate of death of these persister cells. Tolerance, however, is  
42 the transient ability of all bacterial populations to adapt to the environmental pressure or  
43 antibiotics stress and remain alive, which can result in the acquisition of new mutations.  
44 Prolonged exposure to the same stress diminishes this survival ability.<sup>2</sup> The distinction between  
45 persistence and tolerance has been made by the Balaban group, in which persistence was  
46 proposed to be a higher level of tolerance with a lower percentage of viable cells during the  
47 environmental stress.<sup>2</sup> Accordingly, the persistent/tolerant live bacterial population can adapt to  
48 antibiotics at a higher concentration than the minimum inhibitory concentration (MIC), while  
49 maintaining a sensitive antibiotic profile.<sup>2</sup> Thus, Brauner *et al.* proposed a model to define  
50 tolerance and persistence based on the duration required to kill 99% and 99.99% of the bacterial  
51 population.<sup>2</sup> This 0.01-1% of the bacterial population can switch from non-culturable to a  
52 culturable state once the environmental stress has been eliminated.<sup>2</sup>

53 Persisters have been characterised by their reduced metabolism and growth rate, in order to save  
54 energy.<sup>3</sup> They were also shown to stop their replication and become viable but non-culturable,<sup>4</sup> a  
55 dormant stage that has been associated with biofilm formation.<sup>5,6</sup> Both tolerance and persistence  
56 have been linked to antibiotic resistance and recurrent infections.<sup>7,8</sup> Persistence has also been  
57 associated with the formation of a small colony variant (SCV), which is characterised by a slow  
58 growth rate.<sup>9</sup> SCV strains are also associated with recurrent infections,<sup>10,11</sup> due to their decreased  
59 electron transport activity, lower respiration rate and the ability to return to the parent  
60 phenotype.<sup>9-11</sup>

61 The phenomena of persistence is not new, it is an inherent ability of some bacterial species, such  
62 as *Mycobacterium tuberculosis*;<sup>12</sup> however, persistence has also been shown in other bacterial  
63 species such as *Escherichia coli*,<sup>3</sup> *S. aureus*,<sup>13</sup> *Clostridium difficile* and *Salmonella* species.<sup>12,14,15</sup>  
64 The molecular mechanisms underlying persistence are now being extensively studied on these  
65 rapid growing model species. The survival of these persisters is based on few shared key  
66 molecular mechanisms, which are based on oxidative stress, toxin-antitoxin (TA) modules and  
67 quorum sensing.<sup>4,5,16,17</sup> The oxidative stress is a well characterised mechanism, especially with  
68 antibiotics. Under antibiotic stress, cytotoxic ROS are generated to target bacterial proteins,  
69 lipids and DNA, which lead to cell damage and subsequently death.<sup>16</sup> However, persisters have  
70 the ability to suppress the oxidative stress pathway through either scavenging the generated ROS  
71 or producing less toxic radicals.<sup>16</sup> Lower levels of oxidative stress and free radicals prevents  
72 DNA damage, which allows the cells to survive the bactericidal effect of antibiotics. This  
73 mechanism has been reported in *S. aureus*, *E. coli* and *Pseudomonas aeruginosa*.<sup>16</sup>  
74 The detection of these non-culturable cells is not possible by culture-based methods, and their  
75 estimated low percentage, 0.01-1%, necessitated their detection using single-cell approaches.

76 Recent studies have developed single-cell microfluidics, microscopy and cell sorting methods  
77 using fluorescence-activated cell sorting (FACS) to detect and characterise persister cells.<sup>3,18-20</sup>  
78 FACS has also been used to analyse the metabolic and growth state of persisters,<sup>21</sup> identify  
79 heterogeneity in cell division, which protected the cells from the killing effect of the complement  
80 system and antibiotics,<sup>22</sup> and align cell sorting with sequencing to study gene expression of  
81 persisters.<sup>23</sup> The application of single-cell techniques to detect persistence has been reviewed  
82 elsewhere.<sup>24,25</sup> Recently, FACS was applied to detect carbapenem resistance in *Klebsiella*  
83 *pneumoniae*.<sup>26</sup>

84 This study aimed to re-assess the standard MIC methods and investigate the role of three cell-  
85 wall antibiotics in the formation of persistence against *S. aureus* strains. A culture-independent  
86 cell sorting method was developed to assess, detect and quantify live, dead and persister cells in  
87 MIC assays. This quantification data was then correlated with the MIC values of these antibiotics  
88 by the broth micro- and macrodilution methods. The results showed a single-cell based method  
89 that could be used for an in-depth evaluation of the efficacy of antibiotics, based on both the  
90 percentage of live/dead cells and persistence formation. The single-cell sorting of MIC assays  
91 showed that the standard MIC methods may not reflect the potency of antibiotics, show bacterial  
92 heterogeneity and/or detect antibiotic associated persistence.

## 93 **Methods**

### 94 **1- Determination of MIC using standard methods**

95 Determination of MIC was performed using the broth micro- and macrodilution methods  
96 according to the Clinical and Laboratory Standards Institute (CLSI) guidelines.<sup>27</sup> All daptomycin  
97 assays were supplemented with calcium to a final concentration of 50 mg/L.<sup>28</sup> Sensitive and  
98 resistant *S. aureus* strains used in this study are listed in **Table S1**.

99 To determine the MIC by resazurin, a final concentration of 0.04 mM (0.01 mg/mL) resazurin  
100 (Sigma Aldrich) was added aseptically to all MIC plates and tubes, and further incubated at 37 °C  
101 in the dark. All MIC plates and tubes were checked for colour change at 4 and 24 h. All tests  
102 were repeated with two independent cultures and each tested in duplicate.

### 103 **2- Detection of MIC using macrodilution method by FACS**

104 The bacterial cells of the broth macrodilution MIC replicates were washed twice from media by  
105 centrifugation at a maximum speed for 10 min at room temperature and resuspended in 200 µL  
106 of sterile 5 mM HEPES buffer containing 20 mM glucose, after the 24 h incubation. A  
107 subculture of an overnight bacterial culture was washed as previously described as used as a  
108 positive control of live cells. Then, an aliquote of the bacterial subculture was centrifuged and  
109 treated with 80% ethanol for 2 h before washed as previously described and used as the control  
110 dead cells. Then, samples were analysed for live/dead by staining with propidium iodide (PI)  
111 (Sigma) dye at a final concentration of 8 mg/L and incubated for 5 min. Samples were detected  
112 on BD FACSCanto II flow cytometer (BD Biosciences) and analysed using Kaluza Analysis 1.3  
113 software (Beckman Coulter).

114 Unstained bacterial cells were compared using the FSC and SSC (forward and side scatter)  
115 gating (**Figure S1a**). Gate ‘C’ represents live cells and gate ‘D’ represents dead cells (**Figure**  
116 **S1b**). Negative control for media and buffer were used to confirm that the signal is due to the  
117 presence of bacteria. The gates were slightly modified to compensate for the difference between  
118 the antibiotics killing mode of action and a maximum of 10K events was used to standardise the  
119 number of detected events.

### 120 **3- Detection of antibiotic stress level and persistence by FACS**

121 The bacterial cells of the broth macrodilution MIC replicates were washed as previously  
122 described and stained with CELLROX green dye (Life Technology). CELLROX dye was added  
123 at a final concentration of 2.5  $\mu\text{M}$  and incubated for 5 min before sorted. A maximum of 10K  
124 events was used to standardise the number of detected events. Unstained bacterial cells were  
125 compared using the FSC and SSC gating.

## 126 **Results and discussions**

127 The main aim of this study was to identify antibiotic-induced persistence through evaluating the  
128 current standard MIC methods and assessing the efficacy of antibiotics independent of the  
129 culture methods. Vancomycin, a bacteriostatic<sup>29</sup> or slow bactericidal<sup>30</sup> glycopeptide, daptomycin,  
130 a bactericidal lipopeptide<sup>31,32</sup> and dalbavancin, a bactericidal lipoglycopeptide,<sup>33,34</sup> were chosen  
131 for this study due to their bacterial membrane targeting and variable efficacy against selected *S.*  
132 *aureus* strains.

### 133 **1. MIC determination by standard methods**

134 The determination of the MIC was performed by the two-standard broth microdilution and  
135 macrodilution methods to detect and demonstrate the difference in MIC values. Since, the  
136 standard endpoint reading of both methods is by visual identification of the lowest antibiotic  
137 concentration that shows no growth, resazurin dye was added aseptically to assess the sensitivity  
138 of visual detection. Resazurin is a redox dye that changes its colour upon reduction by live cells  
139 and was used in MIC determination but not considered as a standard protocol.<sup>35,36</sup> The final  
140 concentration of the dye was optimised for the lowest detection limit through serial dilutions of  
141 resazurin and bacterial cells. The results showed that 40  $\mu\text{M}$  resazurin (as a final concentration)  
142 had the lowest possible detection limit, which was  $10^7$  cfu/mL live cells and a higher  
143 concentration of resazurin hinders the detectable colour change.

144 Vancomycin MICs by resazurin broth macrodilution showed a 2-fold increase in MIC values  
145 with MRSA and hVISA compared to the microdilution method, differentiating the hVISA strain  
146 from MSSA strains due to the higher number of live cells (**Table 1**). The phenotypic distinction  
147 between some of the hVISA and MSSA strains has always been difficult due to their identical  
148 sensitive MIC rather to an intermediate cut-off using the broth microdilution method.<sup>37,38</sup>  
149 However, these results require an extensive study with a larger number of heterogeneous strains  
150 to prove distinction.

151 Daptomycin showed an increased MIC values of 2- to 4-fold as measured by the resazurin broth  
152 macrodilution method (**Table 1**). All tested strains had MIC values of 1 mg/L while hVISA and  
153 VISA strains had MIC of 4 and 8 mg/L, respectively (**Table 1**). These MIC results suggest that  
154 both strains may have a daptomycin intermediate or resistance profile; however,  $\leq 1$  mg/L is the  
155 only reported<sup>27</sup> daptomycin-sensitive breakpoint.

156 Dalbavancin MIC values increased by 4-fold against all the strains using the resazurin  
157 macrodilution method. Even though the detailed breakpoint of dalbavancin's intermediate-  
158 resistance has not been identified, MSSA and MRSA showed MIC value of 0.25 mg/L, whereas  
159 hVISA and VISA strains had MIC of 0.5 and 1 mg/L, respectively. VRSA strains showed MIC  
160 of 4 and 8 mg/L (**Table 1**). The increase in dalbavancin MICs with increased vancomycin  
161 resistance is due to the similarity in their mode of action in binding to the D-alanyl-D-alanine  
162 residues of the bacterial cell wall.<sup>39,40</sup> However, dalbavancin anchors and dimerises in the  
163 bacterial membrane, which results in a higher binding affinity and effectiveness against VRSA.<sup>39</sup>

164 These results showed higher MIC values for the broth macrodilution compared to the  
165 microdilution method (**Table 1**), as previously reported.<sup>41,42</sup> Vancomycin, daptomycin and  
166 dalbavancin had an increased MIC of 2-, 2-4 and 4-fold with the resazurin macrodilution  
167 method. The increased MIC-fold could be attributed to either the lower effectiveness of some of  
168 these antibiotics, which was masked by the small volume of the microdilution method, the low  
169 sensitivity of the broth microdilution method or the increased total number of live bacterial cells.  
170 However, the CSLI guidelines have the same MIC breakpoints for both broth methods. This may  
171 require further studies using a larger number of bacterial strains to re-define the MIC breakpoints  
172 using both methods.

173

174

175

176

177

178

179

180

181

182 **Table 1.** MIC values of the broth micro- (I) and macrodilution (A) methods with (R) and without  
 183 resazurin. The results are representative of four replicates in two independent assays. Values in  
 184 bold are the more frequent values (n=3).

185

186

Strains	Vancomycin MIC (mg/L)				Daptomycin MIC (mg/L)				Dalbavancin MIC (mg/L)			
	I	I_R	A	A_R	I	I_R	A	A_R	I	I_R	A	A_R
MSSA (ATCC 25923)	2	2	2	2	<b>0.5-1</b>	<b>0.5-1</b>	1	1	0.06	0.06	0.25	0.25
MSSA (ATCC 29213)	1	1	<b>1-2</b>	2	0.5-1	<b>0.5-1</b>	<b>0.5-1</b>	1	<b>0.06-0.12</b>	<b>0.06-0.12</b>	0.25	0.25
MRSA (ATCC 43300)	1	1	<b>2-1</b>	2	<b>0.25-0.5</b>	0.25- <b>0.5</b>	0.5- <b>1</b>	1	0.03- <b>0.06</b>	0.03- <b>0.06</b>	0.12- <b>0.25</b>	0.25
VISA (NARSA 17)	8	8	8	8	4	4	4	8	0.25	0.25- <b>0.5</b>	1	1
hVISA (ATCC 700698)	2	2	4	4	1	<b>1-2</b>	2	4	0.12	0.12- <b>0.25</b>	0.5	0.5
VRSA (NARSA VRS3b)	16	<b>32-64</b>	>64	>64	0.5	0.5	<b>0.5-1</b>	1	<b>0.5-1</b>	1-2	2	4
VRSA (NARSA VRS4)	>64	>64	>64	>64	1	1	1	1	2	4	4	8

## 187 2. Evaluation of MIC by FACS


188 In order to assess the potency of these three antibiotics against the tested strains, replicates of the  
 189 broth macrodilution MIC were analysed by FACS to detect and sort single cells. Single-cell



190 sorting was performed to assess the actual percentage of live and dead cells using PI<sup>43</sup> at 24 h  
 191 endpoint. PI is a cell-impermeant, non-fluorescent dye that is only fluorescent when bound to  
 192 bacterial DNA due to membrane damage. Positive controls of live and dead cells were used to  
 193 identify the gates.

194 At each antibiotic concentration, the percentage of live cells for each strain was plotted and the  
 195 results were compared to the resazurin macrodilution MIC values. An illustration of live and  
 196 dead plots of dalbavancin treated MRSA is shown in **Figure S2**. At the MIC concentration, as  
 197 determined by the broth macrodilution method, vancomycin MICs showed a range of 1.9-10.2%  
 198 live cells based on the tested strains (**Figure 1**). However, daptomycin and dalbavancin showed a  
 199 range of 17.7-62.9% and 7.5-77.6% live cells based on the strain (**Figure 1**), respectively.  
 200 Consequently, the comparison between the visually detected MIC by broth macrodilution  
 201 method and cell sorting of live/dead cells showed that the minimum inhibitory concentration  
 202 represented from 22-98% of dead cells. This percentage varied based on the antibiotic and the  
 203 tested strain, which cannot be identified using current MIC methods.

204 Interestingly, the vancomycin-treated hVISA strain evidenced to be a heterogeneous strain with a  
 205 higher area under the curve than the MSSA and MRSA strains in concordance with the modified  
 206 population analysis profile (PAP) method.<sup>38,44</sup> The later requires extensive culture methods to  
 207 detect vancomycin-associated bacterial heterogeneity, which has been proposed to be about  $\leq 10^{-5}$   
 208 -  $10^{-6}$  of the population,<sup>38,45</sup> this represents 0.001-0.0001% of bacterial cells in MIC assays.  
 209 However, vancomycin showed 9.8% live persister cells with hVISA, and a plateau in the  
 210 survival kinetics of 2-18.7% live persister cells with all tested strains, which is a higher  
 211 percentage than previously predicted. A plateau in the survival of some bacterial cells was also  
 212 noticed with daptomycin and dalbavancin with 5.4-17.4%, considering only VRSA strains, and  
 213 3.6-11.7%, considering all strains except VRSA, live persisters (**Figure 1**), respectively. Thus,  
 214 persisters represented an average of  $3.7 \pm 1.7\%$  to  $16 \pm 3.7\%$ , which varied based on the strain and  
 215 antibiotic.



216  
 217 **Figure 1.** The percentage of different live bacterial strains as assessed by flow cytometry. Broth  
 218 MIC macrodilution tubes were stained with PI and sorted for live/dead. The data were analysed  
 219 based on the identified gates and the percentage of live cells were plotted. Square-labelled values

220 are the broth MIC macrodilution concentrations. Data (n=3) are shown as means  $\pm$  SD, some  
221 error bars are too small to be visible in the graph.

### 222 3. Detection of persisters and heterogeneity

223 The ability to scavenge and lower the generated ROS under stress was used to detect persisters<sup>46</sup>  
224 and the results were compared to the detected live cells; therefore, replicates of the macrodilution  
225 broth method were stained with the membrane-permanent CELLROX® dye and sorted. Control  
226 live and dead cells of all bacterial strains were stained and showed constant one population  
227 (**Figure S1d and Figure S1e**), a consensus gate was used as a reference ROS level (gate 'ROS')  
228 (**Figure S1c**). The ROS cell sorting results were analysed, compared to the ROS level of the  
229 strain and reference gate, the non-decreasing percentage of live cells, 3.7-16%, when treated at 2-  
230 to 16-fold the MIC and categorised in three groups: 1) the normal, 2) the heterogeneous and 3)  
231 the persistence-triggering group.

232 The normal ROS response showed a concentration-dependent increasing bacterial stress levels,  
233 which was shown with VRSA strains treated with dalbavancin (**Figure 2a**). At a sub-MIC  
234 concentration of dalbavancin, VRSA strains showed elevated ROS levels, which almost half of  
235 the population partially reduced at the MIC concentration. Above the MIC, the concentration-  
236 dependent potency of the antibiotic caused immediate death of most cells, preventing the  
237 management of the antibiotic-associated stress. However, a small percentage of cells (a sporadic  
238 population) maintained a low level of ROS (**Figure 2a**). Similarly, MRSA showed a higher  
239 stress reaction with dalbavancin than vancomycin at MIC concentrations, while VISA showed  
240 the opposite (**Figure 2b**).

241 Heterogeneous bacterial cells had a characteristic ROS response, where hVISA showed a very  
242 low ROS level to all the bacterial population when treated at sub-MIC concentration of  
243 vancomycin or dalbavancin and a slightly elevated stress level at the MIC concentration (**Figure**  
244 **2b**). This ROS response was also identified with the VISA strain, a slow growing strain, which  
245 was shown in **Figure 1** to have a higher area under curve than hVISA and MSSA which is  
246 confirmed to be a SCV strain (**Figure S3 and Table S2**). Interestingly, MSSA showed a distinct  
247 persister population of low ROS level with a slightly different SSC when treated with  
248 vancomycin at 2-fold MIC, which is discussed in **Figure 3 and S4**. These results showed that  
249 heterogeneous bacterial cells had the ability to signal all the bacterial population to reduce their  
250 ROS level and avoid stress-associated cell damage.


251 Daptomycin, surprisingly, showed a persistent bacterial population with MSSA, MRSA and  
252 VRSA strains at 2-fold MIC (**Figure 2c**), and up to 16-fold MIC. Consistently, heterogeneous,  
253 slow growing and SCV strains, hVISA, VISA and MSSA, respectively, showed a low ROS level  
254 at sub-MIC concentrations of daptomycin, as previously identified with vancomycin and  
255 dalbavancin. This detected daptomycin-associated persistence may have partially contributed to  
256 the reported development of daptomycin resistance towards *S. aureus in vivo*.<sup>47-49</sup> Interestingly,  
257 hVISA and MRSA showed different populations at sub-MIC and MIC concentrations of  
258 daptomycin and dalbavancin, respectively, (**Figure 2c and 2b**). These populations were of



259 different low levels of ROS which may also suggest difference in scavenging mechanisms,  
260 which were the outcome of the potency of the antibiotics and the resistance of the strains.


261 It was noticed that some of the detected persister populations had a different SSC from normal  
262 cells (**Figure 2**). As the difference in SSC represents surface roughness, it was suspected that  
263 these populations may have a damaged cell membrane, which would affect the scattered  
264 fluorescence signal. Since they represent a very low percentage, bacterial cells were stressed by a  
265 quick 40% ethanol treatment followed by cell sorting and visualisation by microscopy. The cells  
266 were also stained with a fluorescent membrane dye (FM4-64) to prove that they had acquired  
267 surface granularity. The results showed that all cells had the same SSC when stained with PI or  
268 FM4-64 dye (**Figure S4a**), and only showed higher SSC when stained for ROS (**Figure S4b**).  
269 Microscopic imaging of the samples showed that most of the cells were not fluorescent (**Figure**  
270 **S4c**), as detected by FACS, and some cells showed a half-circled fluorescent ring, which  
271 probably had different light scattering than normal fluorescent cells. These results showed that  
272 the difference in scattering was probably due to the ROS localisation rather than a membrane  
273 damage.

274 (a)




275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288

289 (b)




290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312

313 (c)



314  
315 **Figure 2.** Cell sorting of the ROS generated under the treatment of antibiotics at different  
316 concentrations. ROS gate is the normal free radicals level assessed in the strains. **a)** A  
317 concentration-dependent increasing ROS response of bacterial cells. **b)** The ROS response of  
318 vancomycin and dalbavancin. **c)** The ROS response of daptomycin and its associated persisters.  
319 Data (n=2) are shown to be reproducible over two independent experiments.

320 To confirm the detection of SCV, a heterogeneous small colony with a parent colony and a  
321 parent colony only of MSSA were selected, treated with vancomycin and processed for detection  
322 (**Figure S3**). Cell sorting of the MSSA parent colony containing samples were previously  
323 demonstrated in **Figure 2b**, the SCV mixed colonies samples are shown in **Figure 3**. Samples  
324 were first stained with PI only and showed about 4% live population (gate R), representing  
325 0.27% (gate P) on the SSC. Replicate samples were stained with ROS only and showed about  
326 3.6% of the cells differentiated into higher surface roughness with low ROS levels (red cells,  
327 SSC, gate P) (**Figure 3**). PI was then added on the same ROS treated samples and proved that  
328 these persisters were live (gate L and R) (**Figure 3**). The SCV mixed sample showed slightly  
329 higher percentage of persisters when stained for ROS only compared to **Figure 2b**. This  
330 suggested that the increase in the SCV cells increased the persister population. It also confirmed  
331 that the 3.7-16% of live cells are persisters.



332  
333 **Figure 3.** Detection of *S. aureus* SCV strain (ATCC 25923). The cells were treated with 2 mg/L  
334 vancomycin and stained with PI and CELLROX. The peak tail of gate D (in between the dashed  
335 lines) presents the partially damaged cells. Data (n=2) are shown to be reproducible over two  
336 independent experiments.

#### 337 4. Re-evaluation of the efficacy of antibiotics

338 Even though MIC reflects only the bacterial inhibition, either in a static or cidal mode of action,  
339 but the inhibition of the growth was shown to not be consistent across tested antibiotics and  
340 strains. Therefore, the three antibiotics were re-evaluated for potency based on the death of at  
341 least 85% of the bacterial cells, with taking into consideration the formation of persisters. A heat  
342 map was plotted to visualise the difference in the potency of these antibiotics using MIC,  
343 live/death cell sorting and live/death with persistence detection (**Figure S5**). The MIC  
344 concentration of vancomycin showed  $\geq 85\%$  dead cells with all tested strains, and triggered a  
345 small persistent population with only MSSA. Whereas, daptomycin required a higher  
346 concentration than the MIC across almost all the strains and showed high levels of persisters.  
347 Daptomycin also failed to kill 85% of the MSSA and MRSA cells up to 16 mg/L (**Table 2**).  
348 Dalbavancin, however, showed more effective killing against VISA and VRSA (VRS4) strains  
349 (**Table 2**). Accordingly, the potency of these antibiotics varied from the culture-based MIC  
350 values, and triggered a concentration- or antibiotic-dependent persisters. This evidenced the  
351 limitations of the MIC methods<sup>50</sup> to assess the efficacy of antibiotics, which can be re-evaluated  
352 based on both killing potency, rather than visual inhibition, and persistence formation to help  
353 reduce antimicrobial resistance.

354

355 **Table 2.** FACS-based evaluation of antibiotics based on live/dead percentage and persisters  
 356 formation. Concentrations of the antibiotics presented showed  $\geq 85\%$  dead cells, values in bold  
 357 are higher than MIC values detected by the resazurin macrodilution method, orange-highlighted  
 358 values indicated the detection of persisters by ROS sorting.

MIC FACS ( $>85\%$ dead) (mg/L)	MSSA (ATCC 25923)	MRSA (ATCC 43300)	VISA (NARSA 17)	hVISA (ATCC 700698)	VRSA (NARSA VRS3b)	VRSA (NARSA VRS4)
Vancomycin	2	2	8 <sup>a</sup>	4	N/A	N/A
Daptomycin	$\geq 4$ (60%)	$\geq 1$ (60%)	8	<b>8</b>	<b>4</b>	<b>2</b>
Dalbavancin	<b>2</b>	<b>2</b>	1 <sup>b</sup>	<b>1<sup>c</sup></b>	<b>16</b>	8

359 <sup>a</sup> Represents 98% dead cells, <sup>b</sup> represents 90% dead cells and <sup>c</sup> the increase of the concentration to 2 mg/L  
 360 had 95% dead cells and did not show a population of persistence.

### 361 Conclusion

362 The current standardised MIC methods rely on visual detection, which does not reveal the  
 363 biological state of the bacterial cells.<sup>51</sup> In this study, testing of antibiotics with the broth  
 364 macrodilution method was shown to be more sensitive, potentially due to the presence of a  
 365 higher total number of cells. The use of resazurin increased the sensitivity of the broth  
 366 macrodilution method, which was mainly dependent on the concentration of the dye. A thorough  
 367 quantification of live, dead and persister cells was achieved with single-cell sorting, which  
 368 demonstrated different efficacy of tested antibiotics and strains compared to MIC. Vancomycin  
 369 showed to be very effective against MSSA, MRSA and VISA strains, while daptomycin failed to  
 370 kill more than 60% of the population of MSSA and MRSA using cell sorting. Daptomycin also  
 371 triggered the development of a persistent population with most of the tested strains, which may  
 372 provide an explanation to the rapid development of resistance *in vivo*. The results also showed a  
 373 higher percentage of persistence and heterogeneity in bacterial populations than is currently  
 374 estimated. Therefore, assessment of the current standard MIC methods may be required to  
 375 evaluate the efficacy of antibiotics. This also requires an extensive evaluation of a higher number  
 376 of bacterial strains against all antibiotics to detect bacterial heterogeneity and guide for choice of  
 377 the most suitable antibiotic treatment.

### 378 Acknowledgements and funding

379 The authors acknowledge Prof. Mark Schembri for reviewing the manuscript. The authors also  
 380 acknowledge the National Health and Medical Research Council (NHMRC) Project Grants  
 381 APP631632 and APP1026922 for partially funding this work. M.M.H. is supported by the  
 382 University of Queensland International PhD scholarship. M.A.C. is a NHMRC Principal  
 383 Research Fellow (APP1059354) and currently holds a fractional Professorial Research Fellow  
 384 appointment at the University of Queensland with his remaining time as CEO of Inflazome Ltd.  
 385 The following reagent was provided by the Network on Antimicrobial Resistance in  
 386 *Staphylococcus aureus* (NARSA) for distribution by BEI Resources, NIAID, NIH: NARSA



387 STRAINS *Staphylococcus aureus*, Strain NARSA 17 (HIP06297, NR-45868), VRS3b  
388 (HIP13419, NR-46413) and VRS4 (HIP14300, NR-46414).

### 389 **Transparency declarations**

390 None to declare.

### 391 **References**

- 392 1. Balaban NQ, Gerdes K, Lewis K *et al.* A problem of persistence: still more questions than  
393 answers? *Nat Rev Microbiol* 2013; **11**: 587-91.
- 394 2. Brauner A, Fridman O, Gefen O *et al.* Distinguishing between resistance, tolerance and  
395 persistence to antibiotic treatment. *Nat Rev Microbiol* 2016; **14**: 320-30.
- 396 3. Balaban NQ, Merrin J, Chait R *et al.* Bacterial persistence as a phenotypic switch. *Science* 2004;  
397 **305**: 1622-5.
- 398 4. Ayrapetyan M, Williams TC, Oliver JD. Bridging the gap between viable but non-culturable and  
399 antibiotic persistent bacteria. *Trends Microbiol* 2015; **23**: 7-13.
- 400 5. Maisonneuve E, Gerdes K. Molecular mechanisms underlying bacterial persisters. *Cell* 2014; **157**:  
401 539-48.
- 402 6. Lewis K. Persister cells, dormancy and infectious disease. *Nat Rev Microbiol* 2007; **5**: 48-56.
- 403 7. Levin-Reisman I, Ronin I, Gefen O *et al.* Antibiotic tolerance facilitates the evolution of  
404 resistance. *Science* 2017; **355**: 826-30.
- 405 8. Vogwill T, Comfort AC, Furio V *et al.* Persistence and resistance as complementary bacterial  
406 adaptations to antibiotics. *J Evol Biol* 2016; **29**: 1223-33.
- 407 9. Proctor RA, von Eiff C, Kahl BC *et al.* Small colony variants: a pathogenic form of bacteria that  
408 facilitates persistent and recurrent infections. *Nat Rev Microbiol* 2006; **4**: 295-305.
- 409 10. Vaudaux P, Francois P, Bisognano C *et al.* Increased expression of clumping factor and  
410 fibronectin-binding proteins by hemB mutants of *Staphylococcus aureus* expressing small colony variant  
411 phenotypes. *Infect Immun* 2002; **70**: 5428-37.
- 412 11. Kahl BC, Becker K, Loffler B. Clinical significance and pathogenesis of *Staphylococcal* small colony  
413 variants in persistent infections. *Clin Microbiol Rev* 2016; **29**: 401-27.
- 414 12. Monack DM, Mueller A, Falkow S. Persistent bacterial infections: the interface of the pathogen  
415 and the host immune system. *Nat Rev Microbiol* 2004; **2**: 747-65.
- 416 13. Conlon BP, Rowe SE, Gandt AB *et al.* Persister formation in *Staphylococcus aureus* is associated  
417 with ATP depletion. *Nat Microbiol* 2016; **1**: 16051.
- 418 14. Fisher RA, Gollan B, Helaine S. Persistent bacterial infections and persister cells. *Nat Rev*  
419 *Microbiol* 2017; **15**: 453-64.
- 420 15. Amato SM, Fazen CH, Henry TC *et al.* The role of metabolism in bacterial persistence. *Front*  
421 *Microbiol* 2014; **5**: 70.
- 422 16. Kint CI, Verstraeten N, Fauvart M *et al.* New-found fundamentals of bacterial persistence. *Trends*  
423 *Microbiol* 2012; **20**: 577-85.
- 424 17. Hong-Geller E, Micheva-Viteva SN. Targeting Bacterial Persistence to Develop Therapeutics  
425 Against Infectious Disease. In: Vallisuta O, Olimat S, eds. *Drug Discovery and Development - From*  
426 *Molecules to Medicine*. Rijeka: InTech, 2015; 201-18.
- 427 18. Helaine S, Holden DW. Heterogeneity of intracellular replication of bacterial pathogens. *Curr*  
428 *Opin Microbiol* 2013; **16**: 184-91.
- 429 19. Pu Y, Zhao Z, Li Y *et al.* Enhanced efflux activity facilitates drug tolerance in dormant bacterial  
430 cells. *Mol Cell* 2016; **62**: 284-94.



- 431 20. Zare RN, Kim S. Microfluidic platforms for single-cell analysis. *Annu Rev Biomed Eng* 2010; **12**:  
432 187-201.
- 433 21. Orman MA, Henry TC, DeCoste CJ *et al.* Analyzing Persister Physiology with Fluorescence-  
434 Activated Cell Sorting. *Methods Mol Biol* 2016; **1333**: 83-100.
- 435 22. Putrins M, Kogermann K, Lukk E *et al.* Phenotypic heterogeneity enables uropathogenic  
436 *Escherichia coli* to evade killing by antibiotics and serum complement. *Infect Immun* 2015; **83**: 1056-67.
- 437 23. Henry TC, Brynildsen MP. Development of Persister-FACSeq: a method to massively parallelize  
438 quantification of persister physiology and its heterogeneity. *Sci Rep* 2016; **6**: 25100.
- 439 24. Davis KM, Isberg RR. Defining heterogeneity within bacterial populations via single cell  
440 approaches. *Bioessays* 2016; **38**: 782-90.
- 441 25. Shapiro E, Biezuner T, Linnarsson S. Single-cell sequencing-based technologies will revolutionize  
442 whole-organism science. *Nat Rev Genet* 2013; **14**: 618-30.
- 443 26. Mulrone KT, Hall JM, Huang X *et al.* Rapid susceptibility profiling of carbapenem-resistant  
444 *Klebsiella pneumoniae*. *Sci Rep* 2017; **7**: 1903.
- 445 27. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. *CLSI supplement M100S*.  
446 Wayne, PA: Clinical and Laboratory Standards Institute, 2016.
- 447 28. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and  
448 membrane depolarization in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2003; **47**: 2538-44.
- 449 29. LaPlante KL, Leonard SN, Andes DR *et al.* Activities of clindamycin, daptomycin, doxycycline,  
450 linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-  
451 resistant *Staphylococcus aureus* with inducible clindamycin resistance in murine thigh infection and in  
452 vitro pharmacodynamic models. *Antimicrob Agents Chemother* 2008; **52**: 2156-62.
- 453 30. Zhanel GG, Calic D, Schweizer F *et al.* New lipoglycopeptides: a comparative review of  
454 dalbavancin, oritavancin and telavancin. *Drugs* 2010; **70**: 859-86.
- 455 31. Steenbergen JN, Alder J, Thorne GM *et al.* Daptomycin: a lipopeptide antibiotic for the  
456 treatment of serious Gram-positive infections. *J Antimicrob Chemother* 2005; **55**: 283-8.
- 457 32. Heidary M, Khosravi AD, Khoshnood S *et al.* Daptomycin. *J Antimicrob Chemother* 2018; **73**: 1-  
458 11.
- 459 33. Malabarba A, Goldstein BP. Origin, structure, and activity *in vitro* and *in vivo* of dalbavancin. *J*  
460 *Antimicrob Chemother* 2005; **55 Suppl 2**: ii15-20.
- 461 34. Decousser JW, Bourgeois-Nicolaos N, Doucet-Populaire F. Dalbavancin, a long-acting  
462 lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria. *Expert Rev Anti Infect*  
463 *Ther* 2007; **5**: 557-71.
- 464 35. Sarker SD, Nahar L, Kumarasamy Y. Microtitre plate-based antibacterial assay incorporating  
465 resazurin as an indicator of cell growth, and its application in the *in vitro* antibacterial screening of  
466 phytochemicals. *Methods* 2007; **42**: 321-4.
- 467 36. Palomino JC, Martin A, Camacho M *et al.* Resazurin microtiter assay plate: simple and  
468 inexpensive method for detection of drug resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents*  
469 *Chemother* 2002; **46**: 2720-2.
- 470 37. Hiramatsu K, Igarashi M, Morimoto Y *et al.* Curing bacteria of antibiotic resistance: reverse  
471 antibiotics, a novel class of antibiotics in nature. *Int J Antimicrob Agents* 2012; **39**: 478-85.
- 472 38. Howden BP, Davies JK, Johnson PD *et al.* Reduced vancomycin susceptibility in *Staphylococcus*  
473 *aureus*, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains:  
474 resistance mechanisms, laboratory detection, and clinical implications. *Clin Microbiol Rev* 2010; **23**: 99-  
475 139.
- 476 39. Smith JR, Roberts KD, Rybak MJ. Dalbavancin: a novel lipoglycopeptide antibiotic with extended  
477 activity against Gram-positive infections. *Infect Dis Ther* 2015; **4**: 245-58.

- 478 40. Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: a novel antimicrobial. *Int J Clin Pract* 2007; **61**:  
479 853-63.
- 480 41. Vaudaux P, Huggler E, Bernard L *et al*. Underestimation of vancomycin and teicoplanin MICs by  
481 broth microdilution leads to underdetection of glycopeptide-intermediate isolates of *Staphylococcus*  
482 *aureus*. *Antimicrob Agents Chemother* 2010; **54**: 3861-70.
- 483 42. Lin G, Pankuch G, Appelbaum PC *et al*. Antistaphylococcal activity of oritavancin and its  
484 synergistic effect in combination with other antimicrobial agents. *Antimicrob Agents Chemother* 2014;  
485 **58**: 6251-4.
- 486 43. Berney M, Hammes F, Bosshard F *et al*. Assessment and interpretation of bacterial viability by  
487 using the LIVE/DEAD BacLight Kit in combination with flow cytometry. *Appl Environ Microbiol* 2007; **73**:  
488 3283-90.
- 489 44. Wootton M, Howe RA, Hillman R *et al*. A modified population analysis profile (PAP) method to  
490 detect hetero-resistance to vancomycin in *Staphylococcus aureus* in a UK hospital. *J Antimicrob*  
491 *Chemother* 2001; **47**: 399-403.
- 492 45. Yusof A, Engelhardt A, Karlsson A *et al*. Evaluation of a new Etest vancomycin-teicoplanin strip  
493 for detection of glycopeptide-intermediate *Staphylococcus aureus* (GISA), in particular, heterogeneous  
494 GISA. *J Clin Microbiol* 2008; **46**: 3042-7.
- 495 46. Orman MA, Brynildsen MP. Inhibition of stationary phase respiration impairs persister formation  
496 in *E. coli*. *Nat Commun* 2015; **6**: 7983.
- 497 47. Skiest DJ. Treatment failure resulting from resistance of *Staphylococcus aureus* to daptomycin. *J*  
498 *Clin Microbiol* 2006; **44**: 655-6.
- 499 48. Hayden MK, Rezai K, Hayes RA *et al*. Development of Daptomycin resistance in vivo in  
500 methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol* 2005; **43**: 5285-7.
- 501 49. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-  
502 unresponsive *Staphylococcus aureus* bacteraemia in a daptomycin-naive patient--a review of the  
503 literature. *Eur J Clin Microbiol Infect Dis* 2011; **30**: 603-10.
- 504 50. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of  
505 action in the treatment of Gram-positive bacterial infections. *Clin Infect Dis* 2004; **38**: 864-70.
- 506 51. Wootton M, MacGowan AP, Howe RA. Towards better antimicrobial susceptibility testing:  
507 impact of the Journal of Antimicrobial Chemotherapy. *J Antimicrob Chemother* 2017; **72**: 323-9.

508